PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

For advanced endometrial cancer, chemotherapy plus immunotherapy improves outcomes

2023-03-28
(Press-News.org) Endometrial cancer, which makes up about 90% of uterine cancers, will be diagnosed in more than 65,000 people in the United States this year. It is the fourth most common cancer in women and is one of the few cancers that is increasing in incidence and mortality. Unfortunately, very few treatments have been developed specifically for endometrial cancer.

Now, new research published March 27, 2023, in The New England Journal of Medicine finds adding the immunotherapy drug pembrolizumab (Keytruda®) to standard chemotherapy greatly improves patient outcomes in both patients whose tumors have a genetic alteration leading to mismatch repair (MMR) deficiency and those whose tumors are classified as MMR-proficient. The trial was sponsored by the National Cancer Institute and conducted by NRG Oncology, a National Clinical Trials Network group. Physician-scientist Carol Aghajanian, MD, Chair of the NRG Oncology Gynecologic Cancer Committee and Chief of Gynecologic Medical Oncology at Memorial Sloan Kettering Cancer Center (MSK), oversaw the trial.

“The magnitude of the benefit that was seen for many of these patients was profound,” says Dr. Aghajanian, the paper’s senior author.

The results were also presented at the Society of Gynecologic Oncology’s annual meeting by the paper’s first author, Ramez Eskander, MD, of the University of California San Diego.

Endometrial Cancer Clinical Trial Results and MMR Patient Representation

There were 816 patients enrolled in the multicenter international trial. They were divided into two independent cohorts (groups): those with tumors that were MMR-deficient and those with tumors that were MMR-proficient.

There was a 70% improvement in progression-free survival (the time it takes for the cancer to recur or progress) in the group with MMR deficiency. Even among patients whose tumors were MMR-proficient, adding the immunotherapy reduced the risk of the cancer progressing by 46%.

“Endometrial tumors are very heterogeneous,” Dr. Ahgajanian says, noting these cancers include many different kinds of cells. “It is important to know the molecular type of a patient’s tumor when studying this disease.”

All of the patients had advanced or metastatic (stage 3 or 4) cancer. Some were newly diagnosed and some had seen their cancer return after earlier treatments — surgery or a combination of surgery and radiation, surgery and chemotherapy, or all three treatments.

The side effects of the treatment were as previously reported for chemotherapy and pembrolizumab.

Previous MSK Research Showed Checkpoint Inhibitor Immunotherapy Could Work Against MMR-Deficient Tumors

Pembrolizumab is a type of immunotherapy drug called a checkpoint inhibitor. The immune system has checkpoints, like brakes, which prevent immune cells from attacking a person’s own body. A checkpoint inhibitor takes the brakes off the immune system, enabling it to better see and fight cancer. Research led by MSK physician-scientist Luis Diaz Jr., MD, Head of MSK’s Division of Solid Tumor Oncology, has shown that patients whose tumors have MMR defects are more likely to respond to checkpoint inhibitors.

Endometrial cancer has one of the highest rates of MMR defects among all solid tumors.

Advancing Research on New Endometrial Cancer Treatments

Based on the research of Dr. Diaz and others, pembrolizumab is already approved for patients with MMR defects who have failed other treatments, regardless of what type of cancer they have. “This treatment is different, because it looks at giving immunotherapy earlier in the course of disease,” Dr. Aghajanian explains. “We know that we can have a greater impact on cancer by moving the most effective treatments earlier, before patients have had other treatments.”

She adds that, currently, other than immune checkpoint inhibitors for patients with MMR-deficient tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, only one treatment has been approved by the U.S. Food and Drug Administration specifically for endometrial cancer. That treatment, a combination of pembrolizumab and the targeted drug lenvatinib (Lenvima®), was approved in 2021 based on a clinical trial led by MSK gynecologic oncologist Vicky Makker, MD.

Dr. Aghajanian stresses the importance of doing more research on endometrial cancer. “Despite it being the fourth most common cancer among women, endometrial cancer is ranked 24th in terms of the amount of funding it receives from the National Cancer Institute,” she says. “There is still so much we don’t know.”

This research was funded by the National Cancer Institute. Merck, the company that makes pembrolizumab, supplied the drug for the study.

Dr. Aghajanian has provided services to Blueprint Medicines (uncompensated).

 

END


ELSE PRESS RELEASES FROM THIS DATE:

ASBMB calls for 10% budget increase for NIGMS

2023-03-28
The American Society for Biochemistry and Molecular Biology submitted testimony to the U.S. House Appropriations Committee March 22 outlining its recommended budgets for major scientific funding agencies. Notably, the society requested a significant 10% increase in the budget for the National Institute of General Medical Sciences, which is part of the National Institutes of Health. “The ASBMB has a longstanding history of advocating for NIGMS and its researchers, and the majority of our members are funded by and rely on NIGMS to advance their research,” Sarina Neote, public affairs director of the ASBMB, said. “The ...

NIH researchers discover new autoinflammatory disease, suggest target for potential treatments

NIH researchers discover new autoinflammatory disease, suggest target for potential treatments
2023-03-28
WHAT: Scientists have identified an autoinflammatory disease caused by mutations in the LYN gene, an important regulator of immune responses in health and disease. Named Lyn kinase-associated vasculopathy and liver fibrosis (LAVLI), the identification sheds light on how genes linked to certain illnesses can potentially be targets for treatment by repurposing existing drugs. The research, published in Nature Communications, was led by Adriana A. de Jesus, M.D. Ph.D., and Raphaela Goldbach-Mansky, M.D., M.H.S. of the Translational ...

KICT develops a ground & structure collapse detection sensor

KICT develops a ground & structure collapse detection sensor
2023-03-28
The Korea Institute of Civil Engineering and Building Technology (KICT, President Kim Byung-suk) developed a smart sensor that detects signs of ground or structure collapses and a real-time remote monitoring system.   The development of the sensor and system began with a search for a method of instant sensing of the collapse of slopes or buildings caused by ground movement for immediate response. This led to the development of a smart sensor that turns on a LED warning light upon detecting ground movement. The ...

Study: “Safer” PFAS in food packaging still hazardous

2023-03-28
Replacement per- and polyfluoroalkyl substances (PFAS) heralded as safe for use in food packaging break down into toxic PFAS that leak into our food and environment, suggests a study published today in Environmental Science & Technology Letters. Due to the known exposure risks of using smaller PFAS molecules like PFOA and PFOS in food-contact materials, many companies have pivoted to using larger polymeric PFAS to make their wrappers, bowls, and other fast-food packaging water- and grease-repellant. ...

Cartesian Therapeutics expands clinical advisory board with five internationally recognized experts in autoimmunity

Cartesian Therapeutics expands clinical advisory board with five internationally recognized experts in autoimmunity
2023-03-28
Gaithersburg, MD—March 28, 2023 – Cartesian Therapeutics, a fully integrated biopharmaceutical company pioneering RNA cell therapy for autoimmune diseases and cancer, today announced the appointment of five internationally recognized experts in autoimmune diseases.  Cartesian’s appointments include distinguished physicians and scientists as leaders in clinical trials and medicine. “Cartesian is proud to have these prestigious, multidisciplinary advisors committed to treating other autoimmune diseases,” said Miloš Miljković, M.D., Chief Medical Officer at Cartesian Therapeutics. “Their perspectives will provide the utmost value ...

New study finds toxic PFAS “forever chemicals” in Canadian food packaging

2023-03-28
Researchers at the University of Toronto, Indiana University and University of Notre Dame have detected levels of toxic PFAS chemicals—short for per- and polyfluoroalkyl substances—for the first time in Canadian fast-food packaging, specifically water-and-grease repellent paper alternatives to plastic.  Published today in Environmental Science and Technology Letters, the findings suggest that food packaging exposes people directly to PFAS, which have been linked to serious health effects such as increased cancer risk and immune system damage, by contaminating the food they eat. Further, once discarded packaging enters waste streams, PFAS enter the environment, where these ...

Eco-efficient cement could pave the way to a greener future

Eco-efficient cement could pave the way to a greener future
2023-03-28
HOUSTON – (March 28, 2023) – The road to a net-zero future must be paved with greener concrete, and Rice University scientists know how to make it. The production of cement, an ingredient in concrete, accounts for roughly 8% of the world’s annual carbon dioxide emissions, making it a significant target of greenhouse gas emissions reduction goals. Toward those efforts, the Rice lab of chemist James Tour used flash Joule heating to remove toxic heavy metals from fly ash, a powdery ...

Advanced electrode to help remediation of stubborn new 'forever chemicals'

Advanced electrode to help remediation of stubborn new forever chemicals
2023-03-28
CHAMPAIGN, Ill. — As new environmental regulations are rolling out to mitigate the industry-retired long-chain chemicals known as PFAS in drinking water, there are concerns regarding a new breed of “forever chemicals” called short-chain PFAS. Research from the University of Illinois Urbana-Champaign is helping shift the focus to include mitigation of the chemicals – which researchers say are just as persistent as, more mobile and harder to remove from the environment than their long-chain counterparts. A ...

How to prepare for ocean acidification, a framework

How to prepare for ocean acidification, a framework
2023-03-28
SAN FRANCISCO, CA (March 28, 2023) — In a paper published today in the journal Environmental Research Letters, an international research team composed of scientists affiliated with more than a dozen institutions, including the California Academy of Sciences, propose a first-of-its-kind framework for governments around the world to evaluate their preparedness for—and guide future policies to address—ocean acidification, among the most dire threats to marine ecosystems.   “Ocean acidification is one of climate change’s silent killers,” says Rebecca Albright, PhD, Academy Curator of Invertebrate Zoology and ...

Even Sonoran Desert plants aren’t immune to climate change

Even Sonoran Desert plants aren’t immune to climate change
2023-03-28
In North America’s hottest, driest desert, climate change is causing the decline of plants once thought nearly immortal and replacing them with shorter shrubs that can take advantage of sporadic rainfall and warmer temperatures.   Many studies have documented how a hotter, drier world is causing a redistribution of plants in temperate mountain regions. A new UC Riverside study documents the unexpected ways plants in part of the Sonoran Desert are doing the same.  “The plants ...

LAST 30 PRESS RELEASES:

Graz University of Technology opens up new avenues in lung cancer research with digital cell twin

Exoplanets are not water worlds

Study shows increasing ‘healthy competition’ between menu options nudges patients towards greener, lower-fat hospital food choices

New insights into melanoma plasticity uncover a critical role of iron metabolism

A graphene sandwich — deposited or transferred?

New light-powered motor fits inside a strand of hair

Oil rig study reveals vital role of tiny hoverflies

Children’s Hospital of Philadelphia researchers boost widespread use of dental varnish across pediatric network

iRECODE: A new computational method that brings clarity to single-cell analysis

New NUS-MOH study: Singapore’s healthcare sector carbon emissions 18% lower than expected, a milestone in the city-state’s net zero journey

QUT scientists create material to turn waste heat into clean power

Major new report sets out how to tackle the ‘profound and lasting impact’ of COVID-19 on cardiovascular health

Cosmic crime scene: White dwarf found devouring Pluto-like icy world

Major report tackles Covid’s cardiovascular crisis head-on

A third of licensed GPs in England not working in NHS general practice

ChatGPT “thought on the fly” when put through Ancient Greek maths puzzle

Engineers uncover why tiny particles form clusters in turbulent air

GLP-1RA drugs dramatically reduce death and cardiovascular risk in psoriasis patients

Psoriasis linked to increased risk of vision-threatening eye disease, study finds

Reprogramming obesity: New drug from Italian biotech aims to treat the underlying causes of obesity

Type 2 diabetes may accelerate development of multiple chronic diseases, particularly in the early stages, UK Biobank study suggests

Resistance training may improve nerve health, slow aging process, study shows

Common and inexpensive medicine halves the risk of recurrence in patients with colorectal cancer

SwRI-built instruments to monitor, provide advanced warning of space weather events

Breakthrough advances sodium-based battery design

New targeted radiation therapy shows near-complete response in rare sarcoma patients

Does physical frailty contribute to dementia?

Soccer headers and brain health: Study finds changes within folds of the brain

Decoding plants’ language of light

UNC Greensboro study finds ticks carrying Lyme disease moving into western NC

[Press-News.org] For advanced endometrial cancer, chemotherapy plus immunotherapy improves outcomes